• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Intersect ENT, Inc. - Common Stock (NQ:XENT)

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EDT, May 12, 2022 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open -
    Bid (Size) 28.24 (1,000)
    Ask (Size) 29.25 (200)
    Prev. Close 28.24
    Today's Range N/A - N/A
    52wk Range N/A - N/A
    Shares Outstanding 33,314,586
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL® Sinus Implant Reduces Healthcare Resource Utilization
    From Intersect ENT, Inc.
    Via Business Wire
    Intersect ENT Reports Third Quarter 2021 Financial Results
    From Intersect ENT, Inc.
    Via Business Wire

    Performance

    More News

    Read More
    First Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe
    From Intersect ENT®, Inc.
    Via Business Wire
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates INOV, LMRK, XENT, JAX; Shareholders are Encouraged to Contact the Firm
    From Halper Sadeh LLP
    Via AccessWire
    Topics Fraud
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates INOV, GTS, XONE, XENT; Shareholders are Encouraged to Contact the Firm
    From Halper Sadeh LLP
    Via AccessWire
    Topics Fraud
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CSOD, XENT, FFWM, RIVE; Shareholders are Encouraged to Contact the Firm
    From Halper Sadeh LLP
    Via AccessWire
    Topics Fraud
    INVESTIGATION: Halper Sadeh LLP Investigates NLOK, XENT, NWHM; Shareholders are Encouraged to Contact the Firm
    From Halper Sadeh LLP
    Via AccessWire
    Topics Fraud
    Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2021
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2021
    Via Benzinga
    The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
    Via Benzinga
    The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
    Via Benzinga
    INTERSECT ENT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intersect ENT - XENT
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Why Intersect ENT Shot 12% Higher on Friday
    Via The Motley Fool
    Intersect ENT Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Intersect ENT, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – XENT
    From Halper Sadeh LLP
    Via Business Wire
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Medtronic Expands Its ENT Portfolio With Intersect ENT Acquisition For $28.25/Share
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Intersect ENT: Q2 Earnings Insights
    Via Benzinga
    Intersect ENT Reports Second Quarter 2021 Financial Results
    From Intersect ENT, Inc.
    Via Business Wire
    U.S Nationwide Commercial Availability of the VenSure™ Balloon Sinus Dilation System and Cube™ Navigation System Highlight Intersect ENT’s Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis
    From Intersect ENT
    Via Business Wire
    Earnings Scheduled For August 6, 2021
    Via Benzinga
    Intersect ENT Sees Q2 Sales Lag Wall Street Estimates; Raises $60M In Debt Funding
    Via Benzinga
    Intersect ENT to Report Second Quarter 2021 Financial Results on August 6
    From Intersect ENT, Inc.
    Via Business Wire
    Intersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term Loan
    From Intersect ENT, Inc.
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2021
    Via Benzinga

    Frequently Asked Questions

    Is Intersect ENT, Inc. - Common Stock publicly traded?
    Yes, Intersect ENT, Inc. - Common Stock is publicly traded.
    What exchange does Intersect ENT, Inc. - Common Stock trade on?
    Intersect ENT, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Intersect ENT, Inc. - Common Stock?
    The ticker symbol for Intersect ENT, Inc. - Common Stock is XENT on the Nasdaq Stock Market
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.